Ballew Advisors’s Akcea Therapeutics Inc AKCA Stock Holding History

Ballew Advisors’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-245	Closed	-$6K	–	490
2018 Q3	$6K	Buy	+245	New	+$7.41K	0.01%	344

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ballew Advisors's AKCA Position: Q4 2018 in Review

Ballew Advisors sold out of Akcea Therapeutics Inc (AKCA) in Q4 2018, closing a stake of 245 shares — an estimated $6K sold.

Ballew Advisors first reported a position in AKCA in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 62 funds tracked by Wall St. Rank hold AKCA as of Q4 2018.

Ballew Advisors reported no remaining Akcea Therapeutics Inc position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 245 Akcea Therapeutics Inc shares in Q4 2018, an estimated $6K.
Ballew Advisors first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Akcea Therapeutics Inc position peaked at $6K in Q3 2018.
62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.